Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFRA3 | O60609 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.42 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18094367 | 1.00 | GFRA3 (0.43) | GFRA3RETCHRNB2CHRNA4TRPM5 | |
| SCHEMBL29649333 | 0.78 | CHRNA7 (0.55) | GFRA3RETCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL15464723 | 0.74 | CHRNB2 (0.57) | GFRA3RETCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL9251756 | 0.72 | HTR2A (0.43) | GFRA3RETCHRNB2CHRNA4PYGL | |
| SCHEMBL30686717 | 0.72 | HTR2A (0.43) | GFRA3RETCHRNB2CHRNA4PYGL | |
| SCHEMBL20722496 | 0.72 | SLC6A4 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA2 | |
| SCHEMBL30968479 | 0.72 | SLC6A4 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA2 | |
| SCHEMBL24781339 | 0.71 | CHRNB2 (0.43) | CHRNB2CHRNA4TRPM5CHRNA7ALDH1A1 | |
| SCHEMBL23977005 | 0.71 | CHRNB2 (0.43) | CHRNB2CHRNA4TRPM5CHRNA7ALDH1A1 | |
| SCHEMBL8300869 | 0.69 | CHRNB2 (0.42) | CHRNB2CHRNA4TRPM5CHRNA7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3076959-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3076959-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9957219-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957219-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957219-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-09-29 | — | — | US | disclosed |
| WO-2015084692-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | GFRA3 2008/4885RET 912/4885CHRNB2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.